
Sex steroids, crucial hormones regulating reproductive organs, can later promote cancer in the breast and prostate. Breast cancer is the most common among women, while prostate cancer ranks second among men. These hormones, androgens, and oestrogens, function through specific receptors, making steroid-receptor interactions a target in cancer therapies. Treatments include inhibiting steroid production, blocking receptor activity, and enzyme inhibition. Enzyme inhibitors lower hormone levels in tumors by limiting production in gonads, hindering activation, or inhibiting local biosynthesis. Some inhibitors are already used, with new compounds in development. Yet, undiscovered enzymes in sex steroid biosynthesis may exist, and recent discoveries like 11-oxygenated androgens suggest more targets and mechanisms for therapy are forthcoming.
Like
Save
Share